Adverum Biotechnologies is in the biotechnology industry and is part of the healthcare sector. The company CEO is Leone Patterson. Adverum Biotechnologies Inc is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye.

Previous Intraday Performance:

The ADVM shares had a previous change of 0.55% which opened at 9.06 and closed at 9.22. It moved to an intraday high of 9.30 and a low of 9.04.

SeekingAlpha:  Adverum Biotechnologies: A High Risk/High Reward Biotech Play In 2019

Historical Performance:

Over the last five trading days, ADVM shares returned 3.71% and in the past 30 trading days it returned 80.78%. Over three months, it changed 157.54%. In one year it has changed 56.27% and within that year its 52 week high was 9.45 and its 52 week low was 2.62. ADVM stock is 251.91% above its 52 week low.

Our calculations result in a 200 day moving average of 4.92 and a 50 day moving average of 6.39. Right now, ADVM stock is trading 87.33% above its 200 day moving average.

SeekingAlpha:  Updated Investment Thesis On Adverum Biotechnologies


The company has a market cap of $584.9m with 63.4m shares outstanding and a float of 58.7m shares. Trading volume was 626,861 shares and has experienced an average volume of 648,012 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Adverum Biotechnologies was -1.18 which ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.28.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019 -0.23
4thQtr 2018 -0.24
3rdQtr 2018 -0.34
2ndQtr 2018 -0.30
1stQtr 2018 -0.30

EPS growth is an important number as it indicates the future prospects of Adverum Biotechnologies; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -38.90% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 74.80% of institutional ownership.

The beta was calculated to be 2.82.

SeekingAlpha:  Updated Investment Thesis On Adverum Biotechnologies

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -32.21%, return on assets is -29.24%, price-to-sales is 416.69 and price-to-book is 3.11.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here